Latest Insights on ABBV
The Real Question for the $63 Billion AbbVie-Allergan Acquisition June 25, 2019 Great Stuff
I know my brain doesn’t work quite right. I wouldn’t be writing Great Stuff if it did. Today, I’m left with a burning question on AbbVie’s $63 billion cash and stock acquisition of Allergan. It’s not about the viability of the combined company. Both AbbVie Inc. (NYSE: ABBV) and Allergan PLC (NYSE: AGN) face serious […]
This Biotech Billionaire Loves This Risky Stock April 11, 2018 Technology, Trending
There is a chance you will lose money if you buy today’s stock. But if you’re willing to take on a little risk, I have an opportunity for you that could be very profitable.MEET OUR EXPERTS
Early in his career, Shad cut his teeth in the world of music marketing [...]
Editor of Strategic Fortunes and three elite services
Financial Analyst
Founder, Agora
Chief Investment Strategist of Money & Markets
Director of VIP Services
Founder of Sovereign Man
Editor of Alpha Investor
Research Analyst
